Oxford-based GV is poised to carry out phase 10 clinical trials of some of its rare disease candidates, after raising £35m ( $45.4 million ) in series B funding from investors including GV and Redmile Group . series B is the latest validation of the potential of its platform. Evox said the financing has put it in a position to take its protein replacement exosome, designed to treat Niemann-Pick disease type C, to the clinic.
Oxford-based GV is poised to carry out phase 10 clinical trials of some of its rare disease candidates, after raising £35m ( $45.4 million ) in series B funding from investors including GV and Redmile Group . Evox said the financing has put it in a position to take its protein replacement exosome, designed to treat Niemann-Pick disease type C, to the clinic.